DDInter1232 DDInter1376
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies. Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC) - as well as adjunctly to _ab externo_ glaucoma surgeries.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Mitomycin {u} (Compound) treats {v} (Disease) stomach cancer
Mitomycin {u} (Compound) binds {v} (Gene) ABCB1
Mitomycin {u} (Compound) upregulates {v} (Gene) STAP2
Mitomycin {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Mitomycin {u} (Compound) downregulates {v} (Gene) MRPL19
Mitomycin {u} (Compound) causes {v} (Side Effect) Acute respiratory distress syndrome
Mitomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gatifloxacin
Mitomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyclophosphamide
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carmustine
Mitomycin (Compound) treats stomach cancer (Disease)
Mitomycin (Compound) binds ABCB1 (Gene)
Mitomycin (Compound) upregulates STAP2 (Gene)
Mitomycin (Compound) is included by Alkylating Activity (Pharmacologic Class)
Mitomycin (Compound) downregulates MRPL19 (Gene)
Mitomycin (Compound) causes Acute respiratory distress syndrome (Side Effect)
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine